Press Releases

Huateng Pharma Elevates Diabetes Drug Development with High-Purity Anti-Diabetes Intermediates

Huateng Pharma introduces advanced anti-diabetes intermediates, such as Canagliflozin, Dapagliflozin, Empagliflozin, and Semaglutide, representing a major step in diabetes treatment. These high-purity compounds have the potential to revolutionize drug development. Huateng Pharma also offers CDMO services to promote collaboration in the pharmaceutical industry.

Biopharma PEG Elevates ADC Development with Monodispersed PEGs in Versatile Scales

Biopharma PEG introduces monodispersed PEGs, including mPEG36-NH2,NH2-PEG24-COOH, OH-PEG9-OH, mPEG8-SPA , for ADC development at diverse scales. R&D Director highlights their role in modulating ADC properties.

uMotif and Cogstate Power CNS Research, Combining Patient-Centric eCOA/ePRO Data Capture Platform with Market-Leading Cognitive Solutions

Companies building on existing studies in areas including psychedelics to better support CNS research with innovations to quantifiably increase data quality, improve study timelines, and enhance the clinical trial site and patient experience

Groundbreaking treatment for Alcohol Use Disorder shown to halve alcohol consumption amongst heavy drinkers in three months at phase II: a new hope for patients

• The trial showed that KT-110 has superior efficacy in reducing alcohol consumption • KT-110 will be deliverable in a once-daily tablet (proprietary formulation) • KT-110’s mode of action is novel to Alcohol Use Disorder (AUD) and works by simultaneously modulating the noradrenergic and serotonergic brain receptors that counteract the neurobiological processes involved in addiction • Alcohol dependence, or AUD, is a serious public health issue and the medical need for the treatment of alcoholism is considerable and unmet • Kinnov Therapeutics expects to have clear guidance from the FDA in early 2024 on the phase III trial

Inizio Medical Calls for Urgent Action to Adopt AI in All Aspects of Healthcare Communication

One of the world’s leading communication companies Inizio Medical has issued an urgent call to action for businesses to adopt AI in all aspects of healthcare communication or risk being left behind by their competitors.

Simbec-Orion and biotx.ai launch strategic partnership to de-risk early-stage drug development with AI supported clinical trial design

Simbec-Orion, a full-service mid-size CRO, and biotx.ai, a developer of AI-enabled causal modelling for drug development, have announced their strategic partnership to bring AI-powered insights and predictive models to support data-driven clinical trial design.

Resolian Acquires China-Based Bioanalytical CRO Denali Medpharma

Resolian, a global bioanalytical contract research organization (CRO) specializing in drug metabolism and pharmacokinetics for small and large molecules, has acquired Denali Medpharma, a leading China-based bioanalytical CRO

Amerigo Scientific Rolls Out Real-Time PCR Kits to Facilitate HAV Research

CD BioSciences Releases Biophysical Analysis Services to Speed Up Drug Discovery and Biomedical Research

Creative Diagnostics Launches Carbamazepine Test Reagents

Creative Diagnostics has announced the release of its new line of Carbamazepine Test Reagents.

STEMart Launches Disinfection Efficacy Studies Services for Medical Devices

STEMart has announced the launch of its Disinfection Efficacy Studies Services in various standards to ensure the safety of medical devices.

New ‘One World, One Health’ Report Shows Critical Need for Closer Collaboration Between Key Stakeholders Across Human, Animal, and Environmental Health

CD Bioparticles Announces the Launch of New Flow Cytometry Particles

CD Bioparticles has announced a range of new Flow Cytometry Particles.

Revolutionizing Metabolomics: Creative Proteomics Unveils LC-MS/MS Untargeted Metabolomics Service

Innovative SILAC-Based Proteomics Analysis Service Launched by Creative Proteomics

Creative Proteomics Introduces Methionine Cycle Analysis Service for Metabolomics Research

BioIVT Expands its Biospecimen Portfolio in Support of Neuroscience Research

BioIVT will be available to discuss its newly expanded, comprehensive portfolio of neuro-related disease and TruNormal® biospecimens at Neuroscience 2023.

Catawba Research Announces the Promotion of Andrew Silverman, Ph.D., to CEO

Catawba Research, a leading clinical research organization with a goal to become the world’s most trusted CRO, is announcing changes to its executive leadership team.

Phastar Offers Pro Bono Support to Medicines Development for Global Health

Phastar Offers Pro Bono Support to Medicines Development for Global Health Supporting medicine development for disadvantaged communities

MIB Agents Now Accepting Applications for Annual OutSmarting Osteosarcoma Research Grants